Daratumumab in the treatment of high-risk MGUS and low-risk smoldering myeloma

Daratumumab in the treatment of high-risk MGUS and low-risk smoldering myeloma

Treatment-Free Ways to Delay Progression | Boston RT Sept 16, 2023Подробнее

Treatment-Free Ways to Delay Progression | Boston RT Sept 16, 2023

Genomic profiling of smoldering myeloma identifies high- and low- risk patientsПодробнее

Genomic profiling of smoldering myeloma identifies high- and low- risk patients

IMWG Conference Series: Reporting from ASH 2022Подробнее

IMWG Conference Series: Reporting from ASH 2022

Multiple Myeloma Precursor Conditions | Overview | Therapeutic InterventionПодробнее

Multiple Myeloma Precursor Conditions | Overview | Therapeutic Intervention

How to Treat MGUS and Smoldering Myeloma with Dr. S. Vincent RajkumarПодробнее

How to Treat MGUS and Smoldering Myeloma with Dr. S. Vincent Rajkumar

About MGUS and Smouldering Multiple MyelomaПодробнее

About MGUS and Smouldering Multiple Myeloma

Clinical Trials for High Risk Smoldering Myeloma PatientsПодробнее

Clinical Trials for High Risk Smoldering Myeloma Patients

Diagnosis and Risk Stratification of Plasma Cell Disorders (pt 1 of 5 - IMF ASH Satellite)Подробнее

Diagnosis and Risk Stratification of Plasma Cell Disorders (pt 1 of 5 - IMF ASH Satellite)

Early prevention of myeloma: dara for high-risk MGUS and low-risk SMMПодробнее

Early prevention of myeloma: dara for high-risk MGUS and low-risk SMM

MCRT New York 2018: Expert Panel Q&A on Multiple Myeloma (Morning Session)Подробнее

MCRT New York 2018: Expert Panel Q&A on Multiple Myeloma (Morning Session)

Living Well with Myeloma: MGUS, Smoldering Myeloma, and Newly DiagnosedПодробнее

Living Well with Myeloma: MGUS, Smoldering Myeloma, and Newly Diagnosed